- Home
- ORIC vs PHAR Comparison
ORIC vs PHAR Comparison
Compare ORIC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- PHAR
- Stock Information
- Founded
- ORIC 2014
- PHAR 1988
- Country
- ORIC United States
- PHAR Netherlands
- Employees
- ORIC N/A
- PHAR N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- PHAR Health Care
- Exchange
- ORIC Nasdaq
- PHAR Nasdaq
- Market Cap
- ORIC 362.9M
- PHAR 731.1M
- IPO Year
- ORIC 2020
- PHAR N/A
- Fundamental
- Price
- ORIC $10.65
- PHAR $9.88
- Analyst Decision
- ORIC Strong Buy
- PHAR Strong Buy
- Analyst Count
- ORIC 8
- PHAR 3
- Target Price
- ORIC $18.83
- PHAR $30.00
- AVG Volume (30 Days)
- ORIC 1.0M
- PHAR 4.3K
- Earning Date
- ORIC 08-11-2025
- PHAR 07-31-2025
- Dividend Yield
- ORIC N/A
- PHAR N/A
- EPS Growth
- ORIC N/A
- PHAR N/A
- EPS
- ORIC N/A
- PHAR N/A
- Revenue
- ORIC N/A
- PHAR $320,708,000.00
- Revenue This Year
- ORIC N/A
- PHAR $13.31
- Revenue Next Year
- ORIC N/A
- PHAR $7.68
- P/E Ratio
- ORIC N/A
- PHAR N/A
- Revenue Growth
- ORIC N/A
- PHAR 24.13
- 52 Week Low
- ORIC $3.90
- PHAR $6.65
- 52 Week High
- ORIC $14.67
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- ORIC 68.45
- PHAR 40.64
- Support Level
- ORIC $9.80
- PHAR $10.46
- Resistance Level
- ORIC $11.19
- PHAR $11.49
- Average True Range (ATR)
- ORIC 0.60
- PHAR 0.31
- MACD
- ORIC -0.05
- PHAR -0.16
- Stochastic Oscillator
- ORIC 76.92
- PHAR 0.00
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.